184 related articles for article (PubMed ID: 35277863)
1. A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.
Falloon K; Cohen B; Ananthakrishnan AN; Barnes EL; Bhattacharya A; Colombel JF; Cross RK; Driscoll MS; Fernandez AP; Ha C; Herfarth H; Horst S; Hou J; Husni ME; Kroshinsky D; Kuhn KA; Lowder CY; Martin G; Parikh D; Sayed CJ; Schocket L; Siaton BC; Vedak P; Weisman MH; Rieder F
Aliment Pharmacol Ther; 2022 May; 55(9):1179-1191. PubMed ID: 35277863
[TBL] [Abstract][Full Text] [Related]
2. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.
Vavricka SR; Rogler G; Gantenbein C; Spoerri M; Prinz Vavricka M; Navarini AA; French LE; Safroneeva E; Fournier N; Straumann A; Froehlich F; Fried M; Michetti P; Seibold F; Lakatos PL; Peyrin-Biroulet L; Schoepfer AM
Inflamm Bowel Dis; 2015 Aug; 21(8):1794-800. PubMed ID: 26020601
[TBL] [Abstract][Full Text] [Related]
3. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
[TBL] [Abstract][Full Text] [Related]
4. The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease.
King D; Chandan JS; Thomas T; Nirantharakumar K; Reulen RC; Adderley NJ; Trudgill N
Inflamm Bowel Dis; 2021 Oct; 27(11):1731-1739. PubMed ID: 34669933
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease.
Karmiris K; Avgerinos A; Tavernaraki A; Zeglinas C; Karatzas P; Koukouratos T; Oikonomou KA; Kostas A; Zampeli E; Papadopoulos V; Theodoropoulou A; Viazis N; Polymeros D; Michopoulos S; Bamias G; Kapsoritakis A; Karamanolis DG; Mantzaris GJ; Tzathas C; Koutroubakis IE
J Crohns Colitis; 2016 Apr; 10(4):429-36. PubMed ID: 26721936
[TBL] [Abstract][Full Text] [Related]
6. Skin Manifestations of Inflammatory Bowel Disease.
Greuter T; Navarini A; Vavricka SR
Clin Rev Allergy Immunol; 2017 Dec; 53(3):413-427. PubMed ID: 28643285
[TBL] [Abstract][Full Text] [Related]
7. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
8. Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
Juliao-Baños F; Arrubla M; Osorio L; Camargo J; Londoño J; Cáceres C; Carvajal J; Mosquera-Klinger G; Donado J
Gastroenterol Hepatol; 2021; 44(6):398-404. PubMed ID: 33172691
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review.
Guillo L; D'Amico F; Danese S; Peyrin-Biroulet L
J Crohns Colitis; 2021 Jul; 15(7):1236-1243. PubMed ID: 33367674
[TBL] [Abstract][Full Text] [Related]
10. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
Fleisher M; Marsal J; Lee SD; Frado LE; Parian A; Korelitz BI; Feagan BG
Dig Dis Sci; 2018 Apr; 63(4):825-833. PubMed ID: 29484571
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
[TBL] [Abstract][Full Text] [Related]
12. Extra-Gastrointestinal Manifestations of Inflammatory Bowel Disease May Be Less Common Than Previously Reported.
Card TR; Langan SM; Chu TP
Dig Dis Sci; 2016 Sep; 61(9):2619-26. PubMed ID: 27193564
[TBL] [Abstract][Full Text] [Related]
13. Important cutaneous manifestations of inflammatory bowel disease.
Trost LB; McDonnell JK
Postgrad Med J; 2005 Sep; 81(959):580-5. PubMed ID: 16143688
[TBL] [Abstract][Full Text] [Related]
14. Disease-related and drug-induced skin manifestations in inflammatory bowel disease.
Hindryckx P; Novak G; Costanzo A; Danese S
Expert Rev Gastroenterol Hepatol; 2017 Mar; 11(3):203-214. PubMed ID: 28095714
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations.
He R; Zhao S; Cui M; Chen Y; Ma J; Li J; Wang X
Front Immunol; 2023; 14():1234535. PubMed ID: 37954590
[TBL] [Abstract][Full Text] [Related]
16. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
[TBL] [Abstract][Full Text] [Related]
17. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management.
Rogler G; Singh A; Kavanaugh A; Rubin DT
Gastroenterology; 2021 Oct; 161(4):1118-1132. PubMed ID: 34358489
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease.
Trikudanathan G; Venkatesh PG; Navaneethan U
Drugs; 2012 Dec; 72(18):2333-49. PubMed ID: 23181971
[TBL] [Abstract][Full Text] [Related]
19. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients.
Farhi D; Cosnes J; Zizi N; Chosidow O; Seksik P; Beaugerie L; Aractingi S; Khosrotehrani K
Medicine (Baltimore); 2008 Sep; 87(5):281-293. PubMed ID: 18794711
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease.
Barreiro-de-Acosta M; Lorenzo A; Domínguez-Muñoz JE
Rev Esp Enferm Dig; 2012 Sep; 104(9):468-72. PubMed ID: 23130854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
